litlas
ログインアカウント作成

Jeffrey Schlom

1970–2025 年に発表

263
論文数
39,566
被引用数
119
h 指数
256
i10 指数

被引用数

Jeffrey Schlom の年別被引用数1970 年: 被引用 10 件1971 年: 被引用 47 件1972 年: 被引用 49 件1973 年: 被引用 16 件1974 年: 被引用 20 件1975 年: 被引用 5 件1976 年: 被引用 4 件1977 年: 被引用 3 件1978 年: 被引用 7 件1979 年: 被引用 6 件1980 年: 被引用 1 件1981 年: 被引用 7 件1982 年: 被引用 10 件1983 年: 被引用 20 件1984 年: 被引用 31 件1985 年: 被引用 63 件1986 年: 被引用 92 件1987 年: 被引用 125 件1988 年: 被引用 115 件1989 年: 被引用 67 件1990 年: 被引用 94 件1991 年: 被引用 70 件1992 年: 被引用 83 件1993 年: 被引用 48 件1994 年: 被引用 65 件1995 年: 被引用 89 件1996 年: 被引用 75 件1997 年: 被引用 90 件1998 年: 被引用 61 件1999 年: 被引用 111 件2000 年: 被引用 171 件2001 年: 被引用 140 件2002 年: 被引用 159 件2003 年: 被引用 149 件2004 年: 被引用 176 件2005 年: 被引用 207 件2006 年: 被引用 184 件2007 年: 被引用 182 件2008 年: 被引用 222 件2009 年: 被引用 191 件2010 年: 被引用 191 件2011 年: 被引用 229 件2012 年: 被引用 285 件2013 年: 被引用 272 件2014 年: 被引用 237 件2015 年: 被引用 256 件2016 年: 被引用 197 件2017 年: 被引用 273 件2018 年: 被引用 275 件2019 年: 被引用 757 件2020 年: 被引用 1,082 件2021 年: 被引用 1,238 件2022 年: 被引用 1,101 件2023 年: 被引用 770 件2024 年: 被引用 1,105 件2025 年: 被引用 560 件2026 年: 被引用 24 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,726 件、この内訳の 33%中国: 引用元論文 1,468 件、この内訳の 13%ドイツ: 引用元論文 602 件、この内訳の 5.3%イギリス: 引用元論文 548 件、この内訳の 4.9%イタリア: 引用元論文 497 件、この内訳の 4.4%フランス: 引用元論文 455 件、この内訳の 4%カナダ: 引用元論文 336 件、この内訳の 3%日本: 引用元論文 298 件、この内訳の 2.6%オランダ: 引用元論文 255 件、この内訳の 2.3%オーストラリア: 引用元論文 254 件、この内訳の 2.2%スペイン: 引用元論文 245 件、この内訳の 2.2%インド: 引用元論文 220 件、この内訳の 1.9%
0%33%その他 21.2%

機関

分野

  • Medicine54.1%
  • Immunology and Microbiology25.4%
  • Biochemistry, Genetics and Molecular Biology15.5%
  • Engineering1.2%
  • Materials Science1%
  • Agricultural and Biological Sciences0.8%
  • その他2%

トピック

  • Cancer Immunotherapy and Biomarkers11.1%
  • Immunotherapy and Immune Responses10.5%
  • CAR-T cell therapy research6%
  • Immune Cell Function and Interaction5.8%
  • Monoclonal and Polyclonal Antibodies Research3.4%
  • Immune cells in cancer3%
  • その他60.2%

共著者

全論文

検索で開く
  1. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

    著者: Eric A. Reits, James W. Hodge, Carla Herberts, Tom A. Groothuis, Mala Chakraborty, Elizabeth K. Wansley, Kevin Camphausen, Rosalie M. Luiten, Arnold H. de Ru, Joost Neijssen, Alexander Griekspoor, Elly Mesman, Frank A. W. Verreck, Hergen Spits, Jeffrey Schlom, Peter A. van Veelen, Jacques Neefjes - The Journal of Cell Biology 2006 被引用: 1,704

  2. Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models

    著者: Sarah Greene, Yvette Robbins, Wojciech K. Mydlarz, Angel P. Huynh, Nicole C. Schmitt, Jay Friedman, Lucas A. Horn, Claudia Palena, Jeffrey Schlom, Dean Y. Maeda, John A. Zebala, Paúl E. Clavijo, Clint Allen - Clinical Cancer Research 2019 被引用: 270

  3. Dual inhibition of TGF‐β and PD‐L1: a novel approach to cancer treatment

    著者: James L. Gulley, Jeffrey Schlom, Mary Helen Barcellos‐Hoff, Xiao‐Jing Wang, Joan Seoane, François Audhuy, Yan Lan, Isabelle Dussault, Aristidis Moustakas - Molecular Oncology 2021 被引用: 169

  4. Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

    著者: Julius Strauss, Christopher R. Heery, Jeffrey Schlom, Ravi A. Madan, Liang Cao, Zhigang Kang, Elizabeth Lamping, Jennifer L. Marté, Renee N. Donahue, Italia Grenga, Lisa M. Cordes, Olaf Christensen, Lisa Mahnke, Christoph Helwig, James L. Gulley - Clinical Cancer Research 2018 被引用: 415

  5. Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-β signaling enables PD-L1–mediated tumor eradication

    著者: Lucas A. Horn, Paul L. Chariou, Sofia R. Gameiro, Haiyan Qin, Masafumi Iida, Kristen Fousek, Thomas J. Meyer, Margaret C. Cam, Dallas B. Flies, Solomon Langermann, Jeffrey Schlom, Claudia Palena - Journal of Clinical Investigation 2022 被引用: 118

  6. Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors

    著者: Marijo Bilušić, Christopher R. Heery, Julie Collins, Renee N. Donahue, Claudia Palena, Ravi A. Madan, Fatima Karzai, Jennifer L. Marté, Julius Strauss, Margaret E. Gatti‐Mays, Jeffrey Schlom, James L. Gulley - Journal for ImmunoTherapy of Cancer 2019 被引用: 273

  7. Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances

    著者: Hanne Lind, Sofia R. Gameiro, Caroline Jochéms, Renee N. Donahue, Julius Strauss, James L. Gulley, Claudia Palena, Jeffrey Schlom - Journal for ImmunoTherapy of Cancer 2020 被引用: 246

  8. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer

    著者: Kristen Hege, Emily K. Bergsland, George A. Fisher, John Nemunaitis, Robert S. Warren, James G. McArthur, Andy Lin, Jeffrey Schlom, Carl H. June, Stephen A. Sherwin - Journal for ImmunoTherapy of Cancer 2017 被引用: 322

  9. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy

    著者: Lillian Sun, Paúl E. Clavijo, Yvette Robbins, Priya Patel, Jay Friedman, Sarah Greene, Rita Das, Chris Silvin, Carter Van Waes, Lucas A. Horn, Jeffrey Schlom, Claudia Palena, Dean Y. Maeda, John A. Zebala, Clint Allen - JCI Insight 2019 被引用: 232

  10. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations

    著者: Kellsye P. Fabian, Michelle R. Padget, Renee N. Donahue, Kristen Solocinski, Yvette Robbins, Clint Allen, John H. Lee, Shahrooz Rabizadeh, Patrick Soon‐Shiong, Jeffrey Schlom, James W. Hodge - Journal for ImmunoTherapy of Cancer 2020 被引用: 149

  11. Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer

    著者: Jason M. Redman, Jay Friedman, Yvette Robbins, Cem Sievers, Xinping Yang, Wiem Lassoued, Andrew Sinkoe, Antonios Papanicolau‐Sengos, Chyi‐Chia Richard Lee, Jennifer L. Marté, Evrim Türkbey, Wojtek Mydlarz, Arjun S. Joshi, Nyall R. London, Matthew Pierce, R. Taylor, Steven Hong, Andrew Nguyen, Patrick Soon‐Shiong, Jeffrey Schlom, James L. Gulley, Clint Allen - Journal of Clinical Investigation 2022 被引用: 78

  12. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies

    著者: Julius Strauss, Margaret E. Gatti‐Mays, Byoung Chul Cho, Andrew Hill, Sébastien Salas, Edward F. McClay, Jason M. Redman, Houssein Abdul Sater, Renee N. Donahue, Caroline Jochéms, Elizabeth Lamping, Andrea Burmeister, Jennifer L. Marté, Lisa M. Cordes, Marijo Bilušić, Fatima Karzai, Laureen S. Ojalvo, Genevieve Jehl, Alex Rolfe, Christian S. Hinrichs, Ravi A. Madan, Jeffrey Schlom, James L. Gulley - Journal for ImmunoTherapy of Cancer 2020 被引用: 159

  13. Viral Vector-Based Therapeutic Cancer Vaccines

    著者: Cecilia Larocca, Jeffrey Schlom - The Cancer Journal 2011 被引用: 219

  14. First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors

    著者: Julius Strauss, Christopher R. Heery, Joseph W. Kim, Caroline Jochéms, Renee N. Donahue, Agnes S. Montgomery, Sheri McMahon, Elizabeth Lamping, Jennifer L. Marté, Ravi A. Madan, Marijo Bilušić, Matthew R. Silver, Elisa Bertotti, Jeffrey Schlom, James L. Gulley - Clinical Cancer Research 2018 被引用: 171

  15. Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells

    著者: Benjamin Boyerinas, Caroline Jochéms, Massimo Fantini, Christopher R. Heery, James L. Gulley, Kwong Y. Tsang, Jeffrey Schlom - Cancer Immunology Research 2015 被引用: 456

  16. A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells

    著者: Justin M. David, Charli Dominguez, Kristen K. McCampbell, James L. Gulley, Jeffrey Schlom, Claudia Palena - OncoImmunology 2017 被引用: 177

  17. Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide

    著者: M. E. Christine Lutsiak, Roshanak Tolouei Semnani, Roberto De Pascalis, S. V. S. Kashmiri, Jeffrey Schlom, Helen Sabzevari - Blood 2005 被引用: 896

  18. An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele

    著者: Caroline Jochéms, James W. Hodge, Massimo Fantini, Rika Fujii, Y. Maurice Morillon, John W. Greiner, Michelle R. Padget, Sarah R. Tritsch, Kwong Y. Tsang, Kerry S. Campbell, Hans Klingemann, Laurent Boissel, Shahrooz Rabizadeh, Patrick Soon‐Shiong, Jeffrey Schlom - Oncotarget 2016 被引用: 182

  19. The immunocytokine NHS-IL12 as a potential cancer therapeutic

    著者: Jonathan K. Fallon, Robert M. Tighe, Giorgio Kradjian, Wilson Guzman, Anna Bernhardt, Berend Neuteboom, Yan Lan, Helen Sabzevari, Jeffrey Schlom, John W. Greiner - Oncotarget 2014 被引用: 159

  20. Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape

    著者: Kristin C. Hicks, Paul L. Chariou, Yohei Ozawa, Christine M. Minnar, Karin M. Knudson, Thomas J. Meyer, Jing Bian, Margaret C. Cam, Jeffrey Schlom, Sofia R. Gameiro - Nature Communications 2021 被引用: 88

  21. Phenotypic plasticity and reduced tissue retention of exhausted tumor-infiltrating T cells following neoadjuvant immunotherapy in head and neck cancer

    著者: Cem Sievers, Marco Craveiro, Jay Friedman, Yvette Robbins, Xinping Yang, Ke Bai, Andrew Nguyen, Jason M. Redman, Raj Chari, Patrick Soon‐Shiong, Jeffrey Schlom, James L. Gulley, Clint Allen - Cancer Cell 2023 被引用: 70

  22. Sublethal Irradiation of Human Tumor Cells Modulates Phenotype Resulting in Enhanced Killing by Cytotoxic T Lymphocytes

    著者: Charlie Garnett‐Benson, Claudia Palena, Mala Chakarborty, Kwong-Yok Tsang, Jeffrey Schlom, James W. Hodge - Cancer Research 2004 被引用: 544

  23. M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine

    著者: Karin M. Knudson, Kristin C. Hicks, Xiaoling Luo, Jin‐Qiu Chen, Jeffrey Schlom, Sofia R. Gameiro - OncoImmunology 2018 被引用: 186

  24. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

    著者: Fatima Karzai, David James VanderWeele, Ravi A. Madan, Helen Owens, Lisa M. Cordes, Amy Hankin, Anna Couvillon, E. Hitt Nichols, Marijo Bilušić, Michael L. Beshiri, Kathleen Kelly, Venkatesh Krishnasamy, Sunmin Lee, Min-Jung Lee, Akira Yuno, Jane B. Trepel, Maria J. Merino, Ryan Dittamore, Jennifer L. Marté, Renee N. Donahue, Jeffrey Schlom, Keith Killian, Paul S. Meltzer, Seth M. Steinberg, James L. Gulley, Jung Min Lee, William L. Dahut - Journal for ImmunoTherapy of Cancer 2018 被引用: 312